BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28202513)

  • 1. Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors.
    Steinberg SM; Shabaneh TB; Zhang P; Martyanov V; Li Z; Malik BT; Wood TA; Boni A; Molodtsov A; Angeles CV; Curiel TJ; Whitfield ML; Turk MJ
    Cancer Res; 2017 Apr; 77(7):1599-1610. PubMed ID: 28202513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
    Knight DA; Ngiow SF; Li M; Parmenter T; Mok S; Cass A; Haynes NM; Kinross K; Yagita H; Koya RC; Graeber TG; Ribas A; McArthur GA; Smyth MJ
    J Clin Invest; 2013 Mar; 123(3):1371-81. PubMed ID: 23454771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
    Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
    J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
    Anastas JN; Kulikauskas RM; Tamir T; Rizos H; Long GV; von Euw EM; Yang PT; Chen HW; Haydu L; Toroni RA; Lucero OM; Chien AJ; Moon RT
    J Clin Invest; 2014 Jul; 124(7):2877-90. PubMed ID: 24865425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
    Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
    Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming Drug Resistance to BRAF Inhibitor.
    Friedman A; Siewe N
    Bull Math Biol; 2020 Jan; 82(1):8. PubMed ID: 31933021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
    Bellmann L; Cappellano G; Schachtl-Riess JF; Prokopi A; Seretis A; Ortner D; Tripp CH; Brinckerhoff CE; Mullins DW; Stoitzner P
    Int J Cancer; 2020 Mar; 146(5):1409-1420. PubMed ID: 31702822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
    Liu S; Tetzlaff MT; Wang T; Yang R; Xie L; Zhang G; Krepler C; Xiao M; Beqiri M; Xu W; Karakousis G; Schuchter L; Amaravadi RK; Xu W; Wei Z; Herlyn M; Yao Y; Zhang L; Wang Y; Zhang L; Xu X
    Pigment Cell Melanoma Res; 2015 Jul; 28(4):431-41. PubMed ID: 25903073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.
    Babagana M; Johnson S; Slabodkin H; Bshara W; Morrison C; Kandel ES
    Mol Carcinog; 2017 May; 56(5):1515-1525. PubMed ID: 28052407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
    Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
    Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
    Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.
    Shen CH; Kim SH; Trousil S; Frederick DT; Piris A; Yuan P; Cai L; Gu L; Li M; Lee JH; Mitra D; Fisher DE; Sullivan RJ; Flaherty KT; Zheng B
    Nat Med; 2016 Sep; 22(9):1056-61. PubMed ID: 27500726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors.
    Hao X; Falo Iii LD; Chen G; Zhang J; Carey CD; Storkus WJ; Falo LD; You Z
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
    Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
    Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas.
    Wang J; Huang SK; Marzese DM; Hsu SC; Kawas NP; Chong KK; Long GV; Menzies AM; Scolyer RA; Izraely S; Sagi-Assif O; Witz IP; Hoon DSB
    J Invest Dermatol; 2015 Feb; 135(2):532-541. PubMed ID: 25243790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
    Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway.
    Gupta R; Bugide S; Wang B; Green MR; Johnson DB; Wajapeyee N
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4583-4591. PubMed ID: 30782837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.
    Shi H; Moriceau G; Kong X; Koya RC; Nazarian R; Pupo GM; Bacchiocchi A; Dahlman KB; Chmielowski B; Sosman JA; Halaban R; Kefford RF; Long GV; Ribas A; Lo RS
    Cancer Discov; 2012 May; 2(5):414-24. PubMed ID: 22588879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. M-CSF as a therapeutic target in BRAF
    Barceló C; Sisó P; de la Rosa I; Megino-Luque C; Navaridas R; Maiques O; Urdanibia I; Eritja N; Soria X; Potrony M; Calbet-Llopart N; Puig S; Matías-Guiu X; Martí RM; Macià A
    Br J Cancer; 2022 Oct; 127(6):1142-1152. PubMed ID: 35725813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
    Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
    Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.